| # | Drug | Count |
|---|---|---|
| 0 | APIXABAN | 1 |
| 1 | ASPIRIN | 1 |
| 2 | ASPIRIN 325 MG | 1 |
| 3 | ASPIRIN 81 MG | 1 |
| 4 | DINUTUXIMAB | 1 |
| 5 | DONANEMAB-AZBT | 1 |
| 6 | TENECTEPLASE | 1 |
| 7 | TIVOZANIB | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DINUTUXIMAB | 1 | 0.0012 |
| 1 | TENECTEPLASE | 1 | 0.0006 |
| 2 | TIVOZANIB | 1 | 0.0006 |
| 3 | DONANEMAB-AZBT | 1 | 0.0003 |
| 4 | APIXABAN | 1 | 0.0000 |
| 5 | ASPIRIN | 1 | 0.0000 |
| # | Drug class | Count |
|---|---|---|
| 0 | Factor Xa Inhibitor [EPC] | 1 |
| 1 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 1 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1 |
| 3 | Platelet Aggregation Inhibitor [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 1 | 0.0009 |
| 1 | Factor Xa Inhibitor [EPC] | 1 | 0.0000 |
| 2 | Platelet Aggregation Inhibitor [EPC] | 1 | 0.0000 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1 | 0.0000 |